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1. Introduction 
 
 
 
Skeletal muscle is the largest component of adipose tissue free body mass in the 
human body. [1] This remarkable part of the body consists of many muscles; each 
is combined by muscle fibers or cells and connective tissues and plays an 
important role in physiologic processes and energy metabolism. The basic unit of 
skeletal muscle is the muscle cell or fiber, a long cylindrical structure containing 
numerous nuclei. Skeletal muscles are voluntary muscles. Without this important 
part of body, no one can sit, stand, walk or does any activity needed for daily life. 
Obviously, the skeletal muscles will be damaged often, as they take part in many 
physical activities. Muscle injuries are one of the most common injuries occurring 
in sports, with an incidence varying from 10% to 55% of all the sustained injuries. 
Muscle injury, defined as injury of skeletal muscle involving the rupture of muscle 
fibres, is one of the most common reasons for consulting a sports medicine 
specialist. Muscular overuse after high force eccentric muscle action is associated 
with structural damage of the contractile apparatus which results by releasing 
muscle proteins. The diagnosis of muscle injuries can be done through several 
techniques: medical examination, imaging techniques and laboratory tests for 
blood analysis. Obviously, the best treatment can be given if the injury is 
recognized in its early stages. The recognition of muscle injury markers is the most 
effective factor to achieve this goal. 
There is a proverb that says: “prevention is better than cure”. It is obviously much 
better and cost effective to prevent the skeletal muscle injuries than to cure them 
after their occurrence. As mentioned above, the recognition of muscle injury 
markers is the most effective factor to diagnose muscle injuries and is also the 
most cost effective to prevent of worsen of muscle injuries.  
Muscle damage after exercise results in a substantial increase in myocellular 
protein levels in the blood. [2] Exercise induced muscle damage is mainly caused 
by strong muscle contraction during intense exercise. In recent decades, some 
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muscle injury markers have been assessed to indicate the skeletal muscle injuries. 
These markers, rather than other techniques, most probably, also provide trainers 
with information about muscle damage in sportsmen and women.  
Accordingly, due to those above mentioned advantages, the biochemical and 
physiological characteristics of some of muscle injury markers have been reviewed 
and summarized in the present study. Subsequently two of those markers were 
evaluated after the low and high intensity exercises in well trained athletes.   
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2. Literature 
 
 
 
There are about 650 muscles in the human body. [3] Muscle tissue is classified 
into three types: 
Skeletal muscles: Skeletal muscle tissue is named for its location, attached  
to bones. All skeletal muscle fibers are not alike in structure or function. Skeletal 
muscles vary considerably in size, shape and arrangement of fibers. An individual 
skeletal muscle may be made up of hundreds, or even thousands of muscle fibers 
bundled together and wrapped in a connective tissue covering.  
Cardiac muscle: Cardiac muscle tissue forms the bulk of the wall of the heart. Like 
skeletal muscle tissue, it is striated.  
Smooth muscles: Smooth muscle tissue is located in the walls of hollow 
Internal structures such as blood vessels, the stomach, intestines, and urinary 
bladders. 
All three types possess the basic characteristics of muscle tissue: 
Extensibility: The ability to stretch 
Elasticity: The ability to return to normal length when the stretching force is 
removed 
Excitability: The ability to be excited by stimuli 
Contractility: The ability to apply tension when stimulated. [4]  
Each muscle is especially suited in both structure and function to its particular 
task. 
Skeletal muscle is a remarkable tissue. Muscle cells are specialized to contract. 
Because of its ability to shorten and produce force, we are able to breathe, walk 
and perform all the tasks and activities required in our daily lives. [5] For a human, 
as for other animals, to move is to survive. And, of course, no muscle contractions 
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are more important than those responsible for the simple movements of breathing.  
[6] Skeletal muscles attach at both ends either directly or indirectly to the skeletal 
system. When the muscle contracts it does not pull mostly on the distal end, but 
rather it pulls toward its middle, exerting equal force on the attachments at both 
ends. Which bone moves as a result of the force depends on the relative stability 
of the bones at the time that is determined, to a large degree, by muscles acting 
as stabilizers. The muscles vary in their size and shapes and arrangement of 
fibers. The basic unit of skeletal muscle is the muscle cell or fiber, a long 
cylindrical structure containing numerous nuclei. An individual skeletal muscle may 
be made up of hundreds, or even thousands, of muscle fibers bundled together 
and wrapped in a connective tissue covering. Each muscle is surrounded by a 
connective tissue sheath called the epimysium. Fascia, connective tissue outside 
the epimysium, surrounds and separates the muscles. Perimysium is connective 
tissue that wraps bundles of muscle fibers, the boundless being known as 
fascicles. Endomysium is connective tissue that wraps each individual muscle 
fiber. The endomysium and perimysium are relatively thin and consist mainly of 
reticular fibers. The epimysium is thicker than the intramuscular sheaths and 
consists of both collagen and reticular fibers. [7] The most obvious structures 
within the muscle fiber are the myofibrils, which are the units responsible for 
contraction and relaxation of the fiber. Each myofibril is from 1 to 2 µm in diameter 
and as long as the entire cell and is separated from its neighbors by mitochondria 
and the sarcoplasmic and transverse tubular systems; in a fiber of 50 µm 
diameter, there are up to 8000 myofibrils. Most of the interior of muscle fiber is 
made up of myofibrils, the protein contractile elements of the cell. About 90% of 
the substances of the myofibrils, consist of boundless of myofilaments, is 
represented by the three proteins: myosin, actin, and tropomyosin. When viewed 
longitudinally under the microscope, each fiber appears as a series of alternating 
light and dark striations.  
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Figure 1: Structure of skeletal muscle (Reproduced from: 
http://people.eku.edu/ritchisong/RITCHISO/301notes3.htm)  
 
 
 
 
Figure 2: A morphological diagram of striated muscle (Reproduced from: 
www.shoppingtrolley.net/skeletal%20muscle.shtml) 
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A muscle can contract with varying degrees of force at any particular time, and the 
amount of force is voluntarily controlled. The force of contraction at a given time is 
controlled by two variables: 
o The number of motor units that are activated 
o The stimulating frequency or rate 
Skeletal muscle fibers are not all the same. 
Type I fibers: These fibers, also called slow twitch or slow oxidative fibers,  
are red and contain large amounts of myoglobin (Mb), many mitochondria and 
many blood capillaries. They have a slow contraction velocity, very resistant to 
fatigue and a high capacity to generate Adenosine Triphosphate (ATP) by 
oxidative metabolic processes. These fibers are suited for endurance trainings. 
Such fibers are found in large numbers in the postural of the neck. 
Type IIa fibers: These fibers, also called fast twitch or fast oxidative fibers,  
are red and contain very large amounts of Mb, very many mitochondria and very 
many blood capillaries. These fibers have a very high capacity for generating ATP 
by oxidative metabolic processes. They have a fast contraction velocity and are 
resistant to fatigue. Such fibers are infrequently found in humans. 
Type IIb fibers: These fibers, also called fast twitch or fast glycolytic fibers,  
are white and contain a low content of Mb, relatively few mitochondria, relatively 
few blood capillaries and large amounts glycogen. They have low resistance to 
fatigue. 
2.1.  Muscle injuries: 
Skeletal muscle cells (fibers), like other body cells, are soft and fragile. (SEER’s 
Training Website. www.web-books.com) Muscle injuries are one of the most 
common traumas occurring in sports, with an incidence varying from 10% to 55% 
of all the sustained injuries. [8] A variety of injuries occur to individual while 
involved in different sports and leisure physical activities. Muscle injuries can be 
classified into two groups, firstly those resulting from direct trauma and secondary 
those that occur as a result of indirect injury generated by excessive pull on the 
muscle. [9] Direct trauma to muscle can result from either penetrating or blunt 
injury. Blunt injury is very common in competitive contact sports such as rugby and 
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football with the muscle being exposed to direct compressive forces. According to 
clinical findings, muscle injuries classify into three categories: [10]   
o Grade I lesions: Delayed onset muscle soreness and elongation, very small 
muscle tear. 
o Grade II lesions: Fibrillar disruption, evident muscle tear. 
o Grade III lesions: Fiber disruption, evident muscle tear. 
Muscle injury can be caused by countusion, strain, or laceration. [8] Muscle 
lacerations are the most uncommon of the muscle injuries occurring in sports, as 
more than 90% of all sports-related injuries, are either contusion or strains. A 
muscle contusion occurs when a muscle is subject to a sudden, heavy 
compressive force, such as a direct blow of the muscle. This kind of muscle 
trauma typically takes place in contact sports, whereas sprinting and jumping are 
the most common activities associated with muscle strains. In strains, an 
excessive tensile force subjected onto the muscle leads to the overstraining of the 
myofibers and consequently to a rupture. Indirect trauma is a result of excessive 
strain on the muscle and often occurs in sports involving sprinting and jumping. 
Some muscles are more susceptible to strain with rectus femoris, semitendinosus, 
and gastrocnemius being the most frequently strained muscles. One of the key 
factors in their susceptibility is that they cross two joints resulting in them being 
subjected to stretch in more than one area. Eccentric exercise is commonly 
associated with this type of injury.  Muscle contusion is second only to strain as 
the leading cause of morbidity from sport-related injuries. [11] Severity depends on 
the site of impact, the activation status of the muscles involved, the age of the 
patient, and the presence of fatigue.   
The detection and diagnosis of muscle injuries is usually performed by several 
techniques: [12] 
- Medical examination: The diagnosis of some injuries is done by medical 
examination. The doctor asks about the symptoms and medical history. [13] Also 
doctor does a physical exam. In strain injury the injured area will be examined for: 
o Tenderness over the area of the muscle 
o Pain, especially when contracting the muscle 
- Imaging techniques: The main objective in imaging an injured muscle is to 
determine the location and extent of involvement. Because of its multiplanar 
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capability and high sensitivity to the hemorrhage and edema that result from soft-
tissue injury, magnetic resonance (MR) imaging is the technique of choice for 
imaging muscles, tendons, and ligaments. [14] MR imaging facilitates the 
diagnostic process primarily by detecting alterations in muscle size or signal 
intensity. [15] MRI and computed axial tomography (CT) are now applied as the 
criterion methods for measuring total-body skeletal muscle mass. [16] Within the 
past decades, it has been established that T2 relaxation time of muscle in proton 
MR images increases during exercise, returning to resting values within 1 hour 
postexercise. [17] Sonography is as useful as MRI in depicting acute hamstring 
injuries and because of lower costs, may be the preferred imaging technique. [18]  
- Laboratory tests for blood analysis: Muscular overuse after high force eccentric 
muscle action is associated with structural damage of the contractile apparatus 
that can be observed as Z-line steaming and myofibrillar disruption. Mechanical 
stress is the major contributing factor for inducing muscle injury, which initiates a 
cascade of processes resulting in skeletal muscle damage and releasing of 
muscle fiber proteins. [19] Muscle injury markers determined by laboratory tests, 
are one of the best recognition means of muscle injuries.  
Obviously, the best treatment can be given if the injury is recognized in its early 
stages. The recognition of muscle injury markers is the most effective factor to 
achieve this goal. 
2.2. Muscle injury markers: 
Advances in biological markers (biomarkers) have facilitated the assessment of 
associations between environmental exposures and potential health effects by 
improving accuracy and precision of measures and helping to identify high-risk 
groups in exposed populations. Biomarkers can be measures of exposure, 
measures of susceptibility (showing either increased or decreased susceptibility to 
disease), or measures of effect, such as the presence of sub clinical disease 
processes or diseases themselves. [20] A biomarker is a molecule that indicates 
an alteration of the physiological state of an individual in relation to health or 
disease state, drug treatment, toxins, and other challenges of the environment. 
[21] Many diagnostic markers are also biomarkers.  
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It is well established that periods of increased contractile activity result in 
significant changes in muscle structure and function. The increased rates of 
protein degradation and amino acid oxidation that occur during exercise have 
been attributed to both lysosomal (cathepsin C, D) and non-lysosomal proteases. 
Lysosomal enzyme activity is generally increased too late in time to account for 
the loss of myofibrillar protein found immediately post-exercise. Belcastro and 
colleagues [22] stated that, in vitro, calpain cleaves a variety of substrates: 
receptor proteins, soluble and membrane associated enzymes, cytoskeletal 
proteins and myofibrillar proteins. They also proposed that calpain initiates the 
exercise-induced changes in myofibrillar turnover and organelle disassembly. 
Although calpain does not degrade actin and myosin, it contributes to their 
release. [10]   
Evaluating of the serum values of muscle injury markers is one of the best indirect 
indices for assessing the muscle injuries. In recent decades some of blood 
markers have been used to assess the muscle injuries, each showing the special 
characteristic issues. The ideal marker should be muscle specific with a high 
intracellular concentration, and it should be rapidly released in the event of injury 
and be stable, maintaining its elevated concentration in blood for an adequate time 
period. It should have a high diagnostic sensitivity, especially in the first few hours 
after the injury, and have a diagnostic specificity as close to 100% as possible.[23]   
In this part of study, some of muscle injury markers will be reviewed and their 
characteristic issues will be summarized. As creatine kinase (CK) and myoglobin 
(Mb) are routinely used to evaluate the injury in laboratory tests, [12] these two 
markers have been reviewed, firstly.  
2.2.1. CK:  
CK or creatine phosphokinase (CPK) is an enzyme that catalyses the  
interconversion of phosphocreatine and ATP. During very intense, short-duration 
activities, CK catalyses the reaction in which the phosphate group from 
phosphocreatine (PCr) is transferred to adenosine diphosphate (ADP) to synthesis 
ATP.  
MgADP⎯ + PCr²⎯ + H+    ------›   MgATP²⎯ + Cr 
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CK is a fast ATP-regenerating enzyme. [24] The CK/PCr system is a temporal 
energy buffer. Total CK levels depend on age, gender, race, muscle mass, 
physical activity and climatic condition. [25] High CK enzyme activity is detectable 
in muscle, heart and brain.  CK activity is also detectable in serum. The 
combination of two subunits results in the formation of three types of isoenzymes: 
CK-MM, CK-BB and the hybrid form of CK-MB are characteristic for muscle, brain 
and heart, respectively.  Figure 1 shows the distribution of CK activities of the 
human body. [26]  
Total CK activities in serum have been investigated extensively to evaluate 
damage to skeletal and cardiac muscle. CK-MM isoforms into three separate 
forms can be used as an early detection marker for exercise-induced skeletal 
muscle injury. [27] D. Kumbhare [28] evaluated the elevation of serum CK 
concentration as an index of muscle injury using lumbar decompression surgery 
(LDS) as a model. In lumbar disc surgery (LS), cutting of muscle is avoided. 
However, injury may be produced in many patients when muscle is stripped from 
vertebral lamina, retracted away from the spine, and held with surgical clamps. 
Contributions might also be made by inadvertent muscle tearing, and pressure at 
retractor contact points. Their findings provided support for the validity of serum 
CK measurement as an index of skeletal muscle injury caused by LDS. 
Although CK is the most common serum marker for skeletal muscle injury, it is not 
ideal for several reasons, including lack of tissue specificity, inability to reveal 
damage to specific skeletal fiber types (fast or slow), and inappropriately low 
values when gluthatione concentrations are decreased because of liver or multiple 
organ failure. [29] Additionally, other causes for low CK activity have been 
described. In multiple organ failure, tissue factors, such as lysosomal enzymes, 
that are able to deactivate CK are released into the circulation. The absence of 
physical exercise in the immobilized critically ill patients contributes to low CK 
activity in serum. Attention should be paid when interpreting serum CK activity, 
especially in clinical conditions associated with low extracellular glutathione 
concentrations.  
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  Figure 3:  Distribution of CK activities in different organs of the human body [26]  
 
2.2.2. Mb:  
Mb is a small monomeric, respiratory hem protein consisting of a single 
polypeptide chain of about 153 amino acid residues which serves as ntracellular 
oxygen storage site. [30]   
The physiological function of the Mb is oxygen storage in the tissues until it is 
utilized during metabolism. It serves in some manners to aid the inflow of oxygen 
into cardiac and red skeletal muscle fibers. [31] When a muscle is exercised, it 
uses up available oxygen. Mb has oxygen bound to it, thus providing an extra 
reserve of oxygen so that the muscle can maintain a high level of activity for a 
longer period of time. The mitochondria of cardiac and red skeletal muscle 
myocytes do not lack for oxygen in normal steady states of sustained work. [32]  
The role of Mb as an oxygen storage protein in the muscles of diving birds and 
mammals is well-established. [33] The Mb content is higher in more aerobic 
muscles and is highest in aerobic muscles with long contraction duration. 
Literature   
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Changes in serum concentration of muscle proteins, such as CK and Mb, after 
exercise are studied to evaluate to use of such proteins as indicator of increased 
muscle membrane vulnerability. Mb in serum is a sensitive index for muscle 
damage, which rapidly appears in the circulation after exercise and reaches a 
peak hours earlier than CK. [34]   
Plasma Mb is closely related to a quadriceps muscle cross-sectional area as a 
robust index of locomotor muscle mass, especially to the mass of Mb-containing 
fiber types that are crucial for daily performance. Functionally important aerobic 
slow-twitch type 1 (and 2a) fibers are the primary source of plasma Mb. [35]   
Mb, the first biochemical marker to be commercially available for the diagnosis of 
acute myocardial infarction (AMI), is rapidly released from the areas of ischemic 
injury over a limited period. [36]   
Mb is a sensitive but non-specific marker of AMI, as it is present in both skeletal 
and cardiac muscle, so its specificity is poor. Mb increases as soon as 1 to 2 hours 
after symptom onset in AMI. In emergency department patients with normal 
cardiac levels of TnI at presentation, a change in Mb provides a highly accurate 
diagnosis of AMI within 90 minutes. [37] It has been suggested that Mb is 
excellently suited for monitoring any form of acute muscle damage or increased 
muscle membrane permeability, be at after training or as a consequent of a 
disease or medication. [34] Angiogenesis, the process of formation of new blood 
vessels, can be therapeutic, as in endogenous response to arterial occlusions or 
when one seeks to deliver growth factors to increase blood flow and treat 
disorders of inadequate tissue perfusion. Nitric oxide (NO) plays a crucial role in 
both the endogenous angiogenic response to ischemia and in the therapeutic 
response sought after administration of growth factors. Hazarika, et al. [38] 
hypothesized that manipulating Mb expression in myocites can alter NO 
availability and thus modulate angiogenesis after hind-limb ischemia in the setting 
of normal endothelial function. They concluded that increased Mb expression in 
myocytes attenuates angiogenesis after hind-limb ischemia by binding NO and 
reducing its bioavailability. Mb can modulate the angiogenic response to ischemia 
even in the setting of normal endothelium. 
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Figure 4: The single polypeptide chain of Mb (Reproduced from: 
http://www.bio.davidson.edu/people/midorcas/animalphysiology/websites/2004/Go
och/oxygen.htm) 
 
 
2.2.3. Fast myosin:  
Myosin is considered to be the molecular motor that converts free energy derived 
from the hydrolysis of ATP into the mechanical work that drives muscle 
contraction. [39] Skeletal muscle myosin has a half-life as long as ~30 days. 
Myosin is composed of at least two low molecular weight protein chains of average 
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molecular weight 20,000-30,000 in addition to the two heavy or fibrous subunits of 
molecular weight 200,000. [40] Biochemical experiments on muscle contractile 
proteins have shown that, during the cross-bridge cycle, actin combines with 
myosin and ATP to produce force, ADP and inorganic phosphate. 
Some of the contractile proteins have different isoforms depending on the type of 
fibre. Myosin, the major structural protein in muscle, [41] has different heavy and 
light isoforms depending on whether the fibre type is fast or slow. Myosin heavy 
chain (MHC) isoforms appear to represent the most appropriate markers for fibre 
type delineation. [42] On this basis, pure fibre types are characterized by the 
expression of single MHC isoform, whereas hybrid fibre type expresses two or 
more MHC isoforms. Fast myosin is characteristic of fast skeletal muscle only, 
while slow myosin is common to skeletal and cardiac muscle. [10] 
 
 
Figure 5: Diagram of interactions of myosin and actin in contraction cycle 
(Reproduced from: http://www.team-andro.com/phpBB3/bizepscurls-t163023-
15.html) 
Human muscles are made up of a mixture of slow and fast fibres with 
approximately 50% of each. Although grade II and grade III lesions are detected 
by measuring of CK activity and both types of myosin, but fast myosin is a highly 
sensitive marker for grade I lesion. Fast myosin is a totally specific marker for 
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skeletal muscle, a property not shared by any of the markers currently in use such 
as CK and myoglobin (Mb). Myosin also has the advantage of being more 
sensitive and more stable in blood. 
2.2.4. Alpha-actin:  
Actin is a globular (G-actin), roughly 42-kDa protein found in eukaryotic cells. The 
tin actin filament is a dimeric polymer of G-actin sub-units arranged like two strings 
of beads twisted together. 
In vertebrates, three main groups of actin isoforms, alpha, beta, and gamma have 
been identified. The alpha actins are found in muscle tissues and are a major 
constituent of the contractile apparatus. The beta and gamma actins co-exist in 
most cell types as components of the cytoskeleton, and as mediators of internal 
cell motility. 
 
 
Figure 6: Diagram of actin filament (Reproduced 
from:www.mona.uwi.edu/fpas/courses/physiology/musc…) 
 
Abundance of α-actin in the cell and its stability over time make it to be a good 
marker for detection of skeletal muscle damage alongside other currently used 
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biological markers. [23] The researchers suggested that skeletal α-actin may be a 
specific marker of muscle damage that could be measured when treating elite 
sportsmen and women.  
In another study, Martinez-Amatn, et al. [43] showed that α-actin is significantly 
increased in the serum of sportspeople with skeletal muscle damage. Their data 
showed that the serum concentration of α-actin is significantly higher in 
sportspeople with muscle damage (10.49 µg/ml) than in uninjured sportspeople 
(3.99 µg/ml). They suggested that the presence of circulating α-actin in the 
bloodstream may reflect cell lesions in patients with skeletal muscle damage. 
According to their new results, α-actin is a new and reliable marker of skeletal 
muscle damage in sportspeople which can be used for detection of muscle injury. 
Possible cross interference between skeletal and cardiac muscle damage can be 
discriminated by the combined use of α-actin and troponin I (TnI). 
 
2.2.5. Skeletal troponin I:  
Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex 
which confers calcium-sensitivity to striated muscle actomyosin ATPase activity. It 
binds to both actin and tropomyosin.  
Troponin is found in both skeletal muscle and cardiac muscle, but the specific 
versions of troponin differ between types of muscle, due to the expression of 
different genes.   
Although, detection of skeletal muscle injury is hampered by a lack of 
commercially assays for serum markers specific for skeletal muscle, serum 
concentrations of skeletal troponin I (sTnI) could meet this need. [44] The 
commonly used serum markers, e.g., lactate dehydrogenase, CK, and Mb lack 
specificity to skeletal tissue. MHC shows a delayed increase after exercise-
induced muscle injury. [45] It is therefore not suitable for early diagnosis. TnI is a 
regulatory protein that is only expressed in striated muscle fibers. Marked increase 
in sTnI can be detected within 2-6 hours from the onset of exercise-induced 
muscle injury, with greater responses occurring for eccentric exercise. 
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A: Crystal structure of skeletal muscle troponin in the Ca2+-activated state 
 
B: Crystal structure of skeletal muscle troponin in the Ca2+ free state 
Figure 7: The crystal structure of skeletal muscle troponin (Reproduced from: 
en.wikipedia.org/wiki/Template:PDB_Gallery/7125) 
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sTnI exists as 2 different isoforms, slow sTnI (ssTnI) and fast sTnI (fsTnI), 
produced in slow-twich (ST) and fast-twitch (FT) fibers, respectively. Skeletal 
muscle injury led to the release of one or both isoforms of sTnI and their modified 
products into serum, activity-induced injury preferentially injured FT fibers. [44] In 
another study, Simpson and colleagues [46] concluded that changes in fsTnI and / 
or ssTnI could be influenced by clinical conditions, directly or indirectly, associated 
with rhabdomyolysis. Acute renal failure, compartmental syndrome, and cardiac 
abnormalities are common complications that can affect either the release or 
clearance of sTnI. 
 
2.2.6. H-FABP:  
At least 9 distinct types of specific proteins with tissue Specific distribution have 
been identified which can reversibly and non-covalently bind fatty acids, enhancing 
their aqueous solubility and facilitating their intracellular translocation. [47, 48]  
The first, Mishkin and colleagues [49] demonstrated the binding of fatty acids to 
specific cytoplasmic proteins in various mammalian tissues. A possible physiologic 
role for these proteins in the transport and metabolism of fatty acids considered. 
This is particularly the case with regard to z protein which binds most of the oleic 
acid in liver supernatant in-vitro, they considered.  
FABP, a small (15 kDa), water soluble, cytoplasmic protein is abundantly 
expressed in tissues with an active fatty acid metabolism like heart and liver. [50] 
Its concentration in the plasma of healthy persons is relatively low (<6 μg/L). [51] 
Its physiologic role is the transport of hydrophobic long chain fatty acids from the 
cell membrane to their intracellular sites of metabolism in the mitochondria, where 
they enter the citric acid cycle. [52] Thus FABPs may regulate cytoplasmic fatty 
acid concentrations and oxidative capacity. The capability of FABPs to bind 
retinoic acid and metabolites of the eicosanoid pathway suggests, moreover, their 
possible participation in cellular growth regulation and differentiation processes.  
There are two main types FABPs:  
o Associated to plasma membrane (FABPpm) 
o Intracellular or cytoplasmic FABPs(FABPc) 
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Chronic changes in cellular lipid metabolism are usually accompanied by 
concomitant adaptations in the tissue contents of both membrane associated and 
cytoplasmic FABPs, which relates to a common response also seen during regular 
physiological stimuli such as development, nutrition, and training.  
Cytoplasmic FABPs are presently known to comprise a family of at least nine 
distinct types of FABP, with each type showing a characteristic pattern of tissue 
distribution. The cytoplasmic FABP content is related to the capacity to oxidize 
fatty acids. For striated muscles the content of heart-type FABP (H-FABP) was 
found to be related to the activity of the mitochondrial marker enzyme cytochrome 
c oxidase. 
Among the members of the FABP family, H-FABP is most widely distributed within 
the organism. [53] H-FABP was first shown to be released from injured 
myocardium in 1988. H-FABP is abundantly expressed in cardiomyocytes, but to a 
lesser extent also in skeletal muscle, distal tubular cells of the kidney, specific 
parts of the brain, lactating mammary glands and placenta. [50] In comparison to 
Mb, because the cardiac tissue content of H-FABP is much higher than that of Mb 
and the normal plasma value of H-FABP is much lower than that of Mb, H-FABP is 
a more sensitive marker of myocardial injury than Mb. 
The long-distance migratory flights of birds are predominantly fueled by the 
oxidation of fatty acids, which are sourced primarily from extracellular adipose 
stores. Pelsers and colleagues [54] measured FABP in samples taken from the 
cardiac, pectoralis, and semimembranosus muscles of a long-distance avian 
migrant, the barnacle goose. This study has been the first time that FABP has 
been quantified in the locomotor muscles of a bird that is capable of migrating long 
distance. The FABP content in the adult barnacle goose skeletal muscles have 
been similar to those have found in the skeletal muscles of higher vertebrates 
such as rats and humans. However, the FABP content of the cardiac muscle of 
barnacle goose has been markedly lower than that of rats or humans, the physical 
demands for migrating geese are at least as high as those of running mammals. In 
Table 1, the FABP content of cardiac and skeletal muscles of human, rat and 
goose has been compared. Vork and colleagues [55] in their study, an ELISA 
assay for the determination of H-FABP in rat muscles, observed a positive 
relationship between the level of H-FABP and the percentage of fiber type I.   
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Figure 8: Diagram of FABP (Reproduced from: en.wikipedia.org/wiki/FABP3) 
 
 
Table 1: The FABP content of cardiac and skeletal muscles of goose, rat and 
human (µg/g wet wt) 
 
Muscle Cardiac muscle Skeletal muscles Reference 
Goose 60 10-100 
Pelsers et al., 
1999 
Rat 740±120 13-303 Vork et al., 1991 
Human 520±60 40-140 
Nieuwenhoven  
et al., [56] 1995 
 
FABP is one of the novel and promising plasma markers for detection of tissue 
injury. [50] H-FABP became recognized as a cardiac marker in the 1990s. [57]  
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H-FABP appears as early as 1.5 hours after onset of acute myocardial infarction  
and is largely exerted from the kidney and eliminated from the blood in 24-36 
hours. [58] Tanaka, et al. [58] reported that the serum and urine samples obtained 
of AMI patients only 1.5 hours after the onset of symptoms showed elevated H-
FABP levels, while in the same serum samples the activity of the myocardial-
specific isoenzyme of CK (CK-MB) was still normal. Monique J. M. de Groot and 
colleagues [59] showed that using individually estimated clearance rates for H-
FABP and Mb, reliable estimates of myocardial infarct size can be obtained within 
24 hours, while for the established markers CK or α-hydroxybutyrate 
dehydrogenase (HBDH), a time span of 72 hours is required. 
The severity of pulmonary embolism (PE) ranges from asymptomatic to 
cardiogenic shock. [60] H-FABP measured on admission in patients with 
confirmed acute pulmonary embolism (APE) is useful for short-term risk 
stratification. It appears to be superior to cardiac troponin I (cTnT), N-terminal pro 
brain natriuretic peptide (NT-proBNP) and Mb in the prediction of 30-day APE-
related mortality. [61]    
H-FABP appears to be a valid serum biomarker for the early diagnosis of stroke. 
[62] H-FABP, troponin-I (TnI), and CK-MB concentrations allowed a correct 
discrimination between AMI (increase of all three markers) and stroke (increase of 
H-FABP with normal TnI and CK-MB). Wunderlich [63] showed for the first time 
quantitative data of serum brain-type (B-) FABP and H-FABP being elevated early 
in acute ischaemic stroke. 
Exercise and physical training have been known to damage the skeletal muscles. 
For the first time Sorichter [64] showed that plasma FABP increases after physical 
exercise by healthy subjects and that its pattern of release into and clearance from 
the blood is similar to that of Mb. In another study the plasma FABP and CK 
activity of a group of junior rowers were measured for 5 weeks. [65] The 
researchers concluded that although both parameters can be used to detect 
exercise-induced muscle damage early, it is speculated that FABP measurement 
will be more important for monitoring acute muscle damage among elite athletes 
after a single training session. The baseline CK is a better indicator for the chronic 
effect of training conducted on the previous 2 days of exercise training. Malek, et 
al. [66] investigated whether H-FABP plasma concentration increases in healthy 
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subjects after exercise. They observed that the H-FABP concentration increased 
on exercise in healthy subjects independently of the time of the run, time-to-test 
and hours of training per week.  
2.2.7. Mb/FABP ratio:  
Mb and FABP each are useful as early biochemical markers of muscle injury. 
Nieuwenhoven and colleagues [67] evaluated the plasma ratio of Mb over FABP to 
distinguish myocardial from skeletal muscle damage. In human heart tissue, the 
Mb/FABP ratio is 4.5 and in skeletal muscles varies from 21 to 73. In Table 2 the 
ratio of Mb over FABP has been compared in cardiac and skeletal muscle and 
also in serum and plasma of patients. 
 
Table 2: The ratio of Mb over FABP in heart, skeletal muscles, plasma and serum 
of patients 
Heart * 
Various skeletal 
muscles 
Plasma ** Serum *** 
4.5 ± 0.8 21-73 4.4 ± 1.4 45 ± 22 
  
 * In intact human heart, obtained from autopsy 
** Over 24 h after AMI      
 *** In patients who underwent aortic surgery, between 12 to 24 h after surgery 
 
Both Mb and FABP in plasma can be used as markers of loss of cardiac and /or 
skeletal muscle cell integrity. Both proteins show a similar pattern of release into 
and clearance from plasma. The ratio of the plasma or serum concentrations of 
Mb over FABP reflects the ratio in which the proteins occur in the injured tissue. 
Hence, measurement of Mb and FABP in the same blood sample and expression 
of their ratio is useful to determine the origin of the proteins that are released into 
the vascular compartment. In this way, one can discriminate between damage 
inflicted upon cardiac and skeletal muscle tissue.  
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Both plasma FABP and Mb increase after physical exercise by healthy subjects. 
For both FABP and Mb a significant increase reaches earlier (30 minutes) than for 
CK (2 hours), indicating the usefulness of the former for the early detection of 
muscle injury. [64] In addition, both FABP and Mb return to baseline values at 24 
hours after exercise whereas CK remains elevated until (at least) 48 hours after 
exercise. The relatively short half-life of FABP and Mb in plasma relates to their 
rapid elimination from plasma mostly by renal clearance. FABP and Mb, in 
comparison with CK, are also more useful for the separate monitoring of muscle 
injury during repeated exercise bouts. 
The Mb to H-FABP ratio seems to be useful to identify the type of muscle injured. 
[68] New studies are necessary to evaluate its diagnostic accuracy.        
2.3. Measuring and Values:  
Based on assessment of Mb and H-FABP in practical part of the current study, we 
reviewed the laboratory methods for measuring of these two markers. 
2.3.1. Myoglobin (Mb): 
Mb has been measured by the various different immunological methods. Mikhail A. 
Grachev, et al. [69] used a radio immuno assay (RIA) method. In that procedure 
yields had been resulted in 50-60 min after the arrival of the specimen. Thomas 
Olsson [70] and colleagues in their study determined Mb in the range of 10-500 
µg/l by the chemiluminescent luminal reaction. Only 50 µl of serum has been 
needed. However, the chemiluminescent luminal reaction is not specific for Mb 
since also other haemoproteins, e.g., haemoglobin (Hb) will catalyze the 
luminescent agglutination tests for the rapid detection of elevated levels of serum 
Mb were studied by Konings, et al. [71] They concluded that Mb agglutination test 
could be of value in the exclusion of myocardial infarction. Nishida and colleagues 
[72] developed a sensitive sandwich enzyme immunoassay (EIA) for human Mb. 
In their study the mean normal serum concentration of Mb has been 21.5 ± 6.0 
µg/l (mean ± SD) in males (range, 10.5-33) and 16.9 ± 5.8 µg/l in females (range, 
8-31). Mb in the serum is not influenced by storage for a long time or by repeated 
freezing and thawing sample to repeat assays. [73] An automated nephelometric 
immunoassay involving shell/core particles for determination of Mb (Behringwerke) 
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was evaluated with the BNA Nephelometer by Delanghe, et al. [74] In that time 
immunonephelometric determination of serum Mb has been a fast, convenient and 
reliable method appropriate to the emergency laboratory. A turbidimetric 
immunoassay using shell/core particles for determination of myoglobin was 
evaluated of the Behring Turbitimetr analyzer. [75] Values obtained by turbidimetry 
have been comparable to those obtained by the latex agglutination test 
(Behringwerke). Silva, et al. [76] produced monoclonal antibodies useful for the 
rapid measurement of Mb in a one-step, two-site particle concentration 
fluorescence immunoassay (PCFIA).This method is specific for Mb, has good 
analytical precision , and provides results in ~1 h quite comparable with those 
found by RIA. Yoshinori Uji and colleagues [77] described the evaluation of Mb by 
a fully automated immunoturbidimetric quantitation by a latex agglutination 
technique. Serum Mb levels in males have been markedly higher than those in 
females that may be explained by the greater muscle mass in males than females.  
Mario Plebani and Martina Zaninotto [36] evaluated a new method for Mb 
determination using an electrochemical immunosensor that allows the sensitive 
measurement of the marker in less than 15 min. In recent years the useful 
laboratory methods have been developed. Matveeva and colleagues [78] utilized 
enhanced fluorescence on silver island films (SIFs) to develop a sandwich-format 
immunoassay for the cardiac marker Mb. The initial results for the sandwich Mb 
immunoassay ( on SIF-modified surface using wet chemistry) has showed that it is 
possible to detect Mb concentrations below 50 ng/ml, which is lower than clinical 
cut-off for Mb in healthy patients. Recent work has demonstrated an approach to 
independently measure oxygen saturation of Hb and Mb in optical spectra 
collected in vivo. Marcinek et al. [79] described a strategy to quantify the 
contributions of Hb and Mb to in vivo optical spectra. Biochemical analysis of 
muscle homogenates confirmed that the wavelength shift of the combined Hb/Mb 
peak in in vivo spectra reflects the ratio of concentrations (Hb/Mb) in muscle. They 
provided a fully noninvasive approach to measuring local respiration that can be 
adapted for clinical use. Mion and colleagues [80] evaluated the analytical and 
clinical performance of the Evidence Cardiac Panel. The Evidence Cardiac Panel, 
an automated protein biochip microarray, allows the simultaneous determination of 
creatine kinase MB (CK-MB), Mb, glycogen phosphorylase BB (GPBB), H-FABP, 
carbonic anhydrase III (CA III), cardiac troponin I (cTnI). 
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2.3.2. H-FABP: 
An enzyme linked immuno-sorbent assay (ELISA) of the sandwich type for the 
determination of H-FABP was developed by Vork, et al. [55] making use of the 
streptavidin-biotin system. In their study the FABP content of adult rat heart 
muscle was found to be 0.740 ±0.034 mg/g wet weight. The FABP content of a 
number of skeletal muscles varied from 0.023 to 0.303 mg/g wet weight and was 
related to the content of type 1 muscle fibers of these tissues. Crisman, et al. [81] 
showed H-FABP is immunologically distinguishable from the hepatic FABP and 
heart Mb. It appears that H-FABP, like Mb, is an abundant soluble protein found in 
the cytosol. Yasuhiko Ohkaru, et al. [82] developed a sandwich enzyme-linked 
immunosorbent assay (ELISA) for the determination of human heart type fatty 
acid-binding protein (HH-FABP) in human plasma and urine using the combination 
of two distinct monoclonal antibodies (MAbs) directed against human H-FABP 
purified from human heart muscle. The minimum detection limit of the ELISA has 
been 1.25 ng/ml. The normal mean (± SD) level of human H-FABP has been 3.65 
± 1.81 ng/ml, and that in urine has been 3.20 ± 2.70 ng/ml. W. Roos, et al.  [83] 
described the development and characterization of monoclonal antibodies to 
human H-FABP, illustrating the value of BIAcore biosensor methodology as an 
adjuvant to hybridoma technology. They tested the cross-reactivity of other types 
of cytoplasmic FABP by measuring the binding of human intestinal, human liver 
and bovine heart FABP to the monoclonal antibodies. To allow a more rapid 
determination of heart-type FABP concentration in plasma a direct non-competitive 
(sandwich-type) ELISA was developed by Wodzig, et al. [84] which uses high-
affinity monoclonal antibodies to FABP. Total performance time of the one-step 
immunoassay is 45 minutes. The serum FABP concentration measured in 79 
healthy individuals has been 1.6 (0.8) [mean (SD), range 0.3-5.0] µg/L. Robers, et 
al. [85] found that the simplicity, reproducibility, and full automation in a widely 
used clinical chemistry analyzer like the COBAS MIRA seem to be factors of 
choice for the FABP latex immunoassay for routine clinical diagnosis of  AMI. A 
rapid lateral-flow assay for detection of H-FABP was described by Chan and 
colleagues [86]. They found a good correlation between the conventional ELISA 
and the newly developed lateral-flow assay. The FABP lateral-flow assay can be 
performed at the site of patient care delivery such as emergency department (ED). 
It is a quantitative test using a small quantity of sample and returns results within 5 
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min. Van der Voort and colleagues [87] studied a displacement immunosensor for 
continuous measurement of FABP. Such continuous measurement would not only 
be useful for patients entering the ED with chest pain, but may also be applied for 
non-invasive detection of coronary reperfusion. Early detection of tissue injury is in 
general important in stratifying patient treatment and reducing mortality and 
morbidity. Rapid release from injured cells and appearance in plasma, specific and 
high tissue content and low plasma level in normal healthy controls are the 
characteristics of an ideal biochemical marker. A promising marker for early 
detection of tissue injury is FABP. To take full advantage of the characteristics of 
the early marker FABP, the development of a rapid detection method is crucial. So 
in another study, Chan and colleagues [88] reviewed the development of 
immunoassay for the quantification of FABP in buffer, plasma or whole blood, from 
1997 till 2003.They concluded the application of FABP as an early tissue injury 
marker has a great potential for many clinical purpose. Zaninotto, et al. [89] 
evaluated the analytical characteristics of a new quantitative and fully automated 
H-FABP assay (Randox Laboratories Ltd., Crumlin, UK) and compared its clinical 
performance with respect to the Mb assay (Dade Behring, Milan, Italy). The best 
cutt-off and the associated diagnostic efficacy have been 95 µg/L and 89.47% for 
Mb and 5.09 µg/L and 98.70% for H-FABP, respectively. The H-FABP assay 
evaluated is part of a biochemical panel, the Evidence Cardiac Panel (Randox 
Laboratories Ltd., Crumlin, UK), which allows quantitative fully automated 
simultaneous determination of six markers: creatine kinase MB, Mb, glycogen 
phosphorylase BB, H-FABP, carbonic anhydrase III and cardiac troponin I. Sample 
pre-treatment is not necessary, and the time required to process sample and 
obtain all cardiac panel results, as well as the single biochemical marker value, is 
approximately 80 min.  
2.4. Anaerobic Threshold: 
For a long time maximal oxygen uptake as considered to be the best means of 
determining endurance capacity. [90, 91] This is, however, only a valid 
measurement for short-term endurance work loads. A better measure to ascertain 
middle-term and long-term endurance has proven to be the determination of the 
aerobic-anaerobic threshold. Lactate is produced in skeletal muscle as a direct 
result of increased metabolic rate and glycolytic carbon flow. [92] The blood lactate 
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concentration is the result of its production in muscles and appearance in the 
blood and its removal of the blood and catabolization. The rise in lactic acid 
concentration to 4 mmol/l in peripheral blood during gradual increases in 
workloads can be considered as the criteria for the establishment of the aerobic-
anaerobic threshold in spiroergometric testing. As Cunha and colleagues [93]  
stated the anaerobic threshold (AT) can be defined as the exercise intensity above 
which the blood lactate concentration increases over proportionally due to an 
augment in the anaerobic contribution for ATP re-synthesis. Experimental 
evidence indicates a threshold representing a balance between removal and 
release of lactate from and into the plasma compartment. [94] Considering the AT 
at the fixed value of 4  mmol/l lactate does not take into account the individual 
kinetics of the blood lactate concentration curve. Therefore, the individual AT can 
be located above or below the 4 mmol/l blood lactate level. Cordova and 
colleagues [95] used an incremental cycle ergometer to determine the AT defined 
to them as a blood lactate concentration of 3.5 mmol/l. In their study, to determine 
AT, each participant underwent a cycle ergometer test consisting of two 5 minutes 
exercise periods at progressive intensities with a 10 minutes rest between the two 
rounds. Capillary blood samples have been collected at rest both before exercise 
and at the end of each stage at the 1st, 3rd, and 5th minutes of the rest interval. 
Blood lactate concentrations have been determined electroenzymatically and the 
exercise load corresponding to the 3.5 mmol/l lactate threshold has been 
determined by means of linear interpolation. To understand the concept of AT, it is 
important to understand the metabolic systems that provide energy during 
exercise. [96] 
 
2.5. Exercise Metabolism: 
The ability of human to exercise depends on the conversion of chemical energy to 
mechanical energy in skeletal muscle. The source of chemical energy in muscle is 
ATP. The store of ATP in muscle is small and would be quickly consumed in 
contraction muscle if it were not immediately replenished, as the demand for ATP 
can increase more than 100-fold in the transition from rest to maximal exercise. 
During most exercise, the ATP demand and provision are precisely matched and 
the store of ATP in the muscle is maintained. Therefore, the metabolic pathways 
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that provide ATP within contracting skeletal muscle rapidly respond to the 
increased need for ATP during exercise. [97]  
At rest the energy that the body needs is derived almost equally from the 
breakdown of carbohydrates and fats. Proteins serve important functions as 
enzymes that aid chemical reactions and as structural building blocks, but usually 
provide little energy for metabolism. During intense, short-duration muscular effort, 
more carbohydrate is used, with less reliance on fat to generate ATP. Longer, less 
intense exercise utilizes carbohydrate and fat for sustained energy production. [98] 
The amount of carbohydrate utilized during exercise is related to both the 
carbohydrate availability and the muscles’ well-developed system for carbohydrate 
metabolism. Fat provides a large portion of the energy during prolonged, less 
intense exercise.    
To generate ATP, a phosphate group is added to the relatively low-energy 
compound, ADP, a process called phosphorylation. Some ATP is generated 
independent of oxygen availability, and such metabolism is called substrate-level 
phosphorylation. Some other ATP-producing reactions occur without oxygen, a 
process called anaerobic metabolism. When these reactions occur with the aid of 
oxygen, the overall process is called aerobic metabolism, and the aerobic 
conversion of ADP to ATP is oxidative phosphorylation.  
Cells generate ATP through three different processes or systems: 
o The ATP-PCr system (Immediate energy) 
o The lactic acid system (Short-term energy) 
o The aerobic system (Long-term energy) 
The ATP-PCr system (immediate energy) is the quickest source of ATP for muscle 
actions. Performances of short duration and high intensity such as 100-m sprint, 
25-m swim, smashing a tennis ball during the serve, or thrusting a heavy weight 
upwards require an immediate and rapid energy supply. The high energy 
phosphates ATP and PCr stored within muscles almost exclusively provide this 
energy. The term phosphagens identifies these intramuscular energy surces. [99] 
Each kilogram of skeletal muscle stores approximately 5 millimoles (mmol) of ATP 
and 15 mmol of PCr. The quantity of intramuscular phosphagens significantly 
influences ability to generate all out energy for brief duration. The enzyme CK, 
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which triggers PCr hydrolysis to resynthesize ATP, regulates the rate of 
phosphagen breakdown. 
The lactic acid system (Short-term energy) does not produce large amounts of 
ATP. The intramuscular phosphagens must continually resynthesize rapidly for 
strenuous exercise to continue beyond a brief period. During intens exercise, 
intramuscular stored glycogen provides the energy source to phosphorylate ADP 
during anaerobic glycogenolysis. Without adequate oxygen, pyruvate converts to 
lactate. Anaerobic energy for ATP resynthesis from glycolysis can be viewed as 
reserve fuel that activates when the oxygen demand to oxygen utilization ratio 
exceeds 1.0. Anaerobic ATP production remains crucial during a 440-m run, 100-
m swim, or in multiple-sprint sports like ice hockey, field hockey, and soccer. 
These activities require rapid energy transfer that exceeds that supplied by stored 
phosphagens. Despite of limitation of low amount ATP production, the combined 
actions of the ATP-PCr and glycolytic systems allow the muscles to generate force 
even when the oxygen supply is limited. These two systems predominate during 
the early minutes of high-intensity exercise. 
Aerobic metabolic reactions (Long-term energy) provide for the greatest portion of 
energy transfer, particularly when exercise duration extends longer than 2 to 3 
minutes. ATP is provide from food mainly sugar and fat. This system is the prime 
energy source during endurance activities. Oxygen-consuming reactions supply 
the energy for steady-rate exercise, any lactate produced either oxidized or 
reconverts to glucose in the liver, kidneys, and skeletal muscles. No accumulation 
of blood lactate occurs under these metabolic conditions. Some conditions may 
affect the capacity of aerobic exercise. Patients with metabolic syndrome have 
lowered aerobic exercise capacity, which might be due to impaired skeletal muscle 
mitochondrial oxidative phosphorylation and dysregulation of intramyocellular fatty 
acid metabolism. [100]  
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3. Methodology 
 
 
 
Firstly a systematic database search of PubMed, Web of Scholar Google, Web of 
Library of Bielefeld University and also the “Interlibrary Loan” via the later library, 
and hand searching the reference lists of these retrieved articles was performed to 
achieve the potential muscle injury markers. Key words searched were “muscle 
injury markers”, “skeletal muscle injury”, “muscle injuries”, and “sport injuries”.  
3.1. Muscle injury markers: 
Some of muscle injury markers were reviewed, as discussed in chapter 2, and 
have been mentioned below: 
3.1.1. CK:  
This enzyme was found mainly in muscular, electric and nervous organs. [101]  
In veterinary medicine, serum creatine-kinase (CK) activity is mostly used to 
assess skeletal muscle damage. [102]   
3.1.2. Mb:  
Mb is a compact, highly soluble, and typical globular protein and is found in many 
animal cells. [103, 104] Like haemoglobin, it combines reversibly with molecular 
oxygen.  Mb in serum is a sensitive index for muscle damage. 
3.1.3. Fast myosin:  
In mammals, slow/type I fibers express ß-MHC, while fast/type II fibers express 
one or more of the six type II skeletal muscle myosin genes. [105] Human skeletal 
muscle fibers express five highly conserved type-II MHC genes. Fast myosin is a 
totally specific marker for skeletal muscle. 
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3.1.4.  α-actin:  
Cell division, cell motility and the formation and maintenance of specialized 
structures in differentiated cells depend directly on the regulated dynamics of actin 
cytoskeleton. [106] α-actin is a new and reliable marker of skeletal muscle damage 
in sportspeople. 
3.1.5. sTnI:  
sTnI has been identified as a potential marker of skeletal muscle  injury in humans 
and animals. [107] TnI is a regulatory protein that is only expressed in striated 
muscle fibers.  
3.1.6. H-FABP:  
Nine types of cytoplasmic FABP have been well identified up to now. [108] Among 
the members of the FABP family, H-FABP is most widely distributed within the 
organism. H-FABP appears to be a valid serum biomarker for the early diagnosis 
of: AMI, stroke, and acute muscle damage. 
3.1.7. Mb/FABP ratio:  
Both plasma FABP and Mb increase after physical exercise by healthy subjects. 
Since the ratio of Mb over H-FABP differs between heart and skeletal muscles, it 
can be used to differentiate myocardial injury from skeletal muscle injury. It also 
seems to be useful to identify the type of muscle injured. 
In practical part of the current study, we evaluated the effects of low and high 
intensity exercises on serum concentrations of Mb and H-FABP in well-trained 
athletes.  
3.2. Participants: 
We invited the students of sport science through bulletins and also in their classes. 
Five well-trained athletes were enrolled in this study. We explained the risks and 
benefits of study to all participants, 5 well-trained athletes, mean age 36.1 ± 9.98, 
and informed consent letters were obtained from them. All tests were performed in 
a laboratory (temperature 19-22°c, humidity 40-60%) on a motor driven treadmill 
(model Ergo ELG2, Woodway, Germany).  
Methodology   
 
35
3.3. Determining of anaerobic threshold: 
The anaerobic threshold (AT) can be defined as the exercise intensity above 
which the blood lactate concentration increases over proportionally due to an 
augment in the anaerobic contribution for ATP re-synthesis. [93]   
We determined the AT via graded running on a treadmill with increased velocity at 
regular intervals (the velocity was increased 0.4 m/s every 5 minutes). The heart 
rate was controlled regularity and blood samples were taken in small amounts 
from the ear of participants at each increment to determine the lactate 
concentration with an automatic analyser (SUPER GL, Dr. Müller Gerätebau 
GmbH).  According to Heck and colleagues [91] AT is as the running velocity when 
lactate concentration reaches 4 mmol/l.  
3.4. Prolonged constant-load exercise bouts: 
After the determination of AT, participants were scheduled to complete two 30-
minutes exercise bouts. 
3.4.1. Low intensity/horizontal (LH): 
The first constant-load exercise bout consists of 30 minutes of running on treadmill 
at a velocity of 70% of AT and an elevation of 1% [LH: 70%AT, +1%].  
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3.4.2. High intensity/downhill (HD):  
At the second constant-load exercise bout the participants were asked to run for 
30 minutes downhill on the treadmill at a velocity of 90% of AT and 10% 
declination [HD: 90%AT, -10%]. This step was started by warming up of subjects 
on a treadmill at a velocity of almost 55% of AT for 3 minutes.  
All these three steps of the test (determination of AT and two prolonged constant-
load exercise bouts) were performed in three weeks, subsequently for each 
subject.  
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3.5. Blood sampling and markers measuring: 
Capillary blood samples for the determination of H-FABP and Mb were collected 
from a superficial forearm vein in EDTA coated tubes, before the start of the test 
and again one hour after running on the treadmill at each constant-load exercise 
bout.  
According to the instruction of relevant kits, blood samples for determining Mb and 
H-FABP were centrifuged after 20 minutes and after 2 hours, respectively. Plasma 
samples were frozen and stored at -20°C until assayed.  
H-FABP and Mb were measured by quantitative tests based on the principle of a 
solid phase enzyme-linked immunosorbent assay (ELISA) [H-FABP ELISA, 
Myoglobin ELISA, DRG Instruments GmbH, Germany]. 
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3.5.1. Instructions for Mb measuring: 
1- The plasma samples were diluted 10 fold before use. A series of 2 ml micro 
centrifuge tubes were prepared and mixed 20 µl of plasma sample with 180 µl 
of sample diluent. 
2- 20 µl of Mb standards, diluted specimens and diluted controls were dispensed 
into the appropriate coated wells in the holder. 
3- 200 µl of enzyme conjugate reagent was dispensed into each well and 
thoroughly mixed for 30 seconds and incubated at room temperature (18-25°c) 
for 45 minutes. 
4- The incubation mixture was removed by flicking plate contents into a waste 
container. 
5- The microwells were rinsed and flicked 5 times with deionized water. 
6- The wells were striked sharply onto absorbent paper to remove all residual 
water drops. 
7- 100 µl of TMB (tetramethyl-benzidine) reagent solution was dispensed into each 
well and gently mixed for 5 seconds and incubated at room temperature for 20 
minutes. 
8- The reaction was stopped by adding 100 µl of stop solution to each well and 
gently mixed 30 seconds. 
9- The absorbance was read at 450 nm with a microtiter well reader within 15 
minutes. 
3.5.2. Instructions for H-FABP measuring: 
1- The plasma samples were diluted 20 fold prior to use. A series of 2 ml micro 
centrifuge tubes were prepared and mixed 15 µl of plasma sample with 285 µl 
of sample diluent. 
2- 100µl of standard, diluted specimens, and diluted controls were dispensed into 
appropriate coated wells in the holder and incubated on orbital micro plate 
shaker at 750 rpm at room temperature (18-25°c) for 60 minutes. 
Methodology   
 
39
3- The incubation mixture was removed by flicking plate contents into an 
appropriate Bio-waste container. 
4- The microtiter wells were rinsed and flicked 5 times with 300 µl working wash 
buffer. 
5- The wells were striked sharply onto absorbent paper to remove all residual 
water droplets. 
6- 100 µl of enzyme conjugate reagent was dispensed into each well and 
incubated on orbital micro-plate shaker at 750 rpm at room temperature (18-
25°c) for 60 minutes. 
7- The incubation mixture was removed by flicking plate contents into an 
appropriate Bio-waste container. 
8- The microtiter wells were rinsed and flicked 5 times with 300 µl working wash 
buffer. 
9- The wells were striked sharply onto absorbent paper to remove all residual 
water droplets. 
10- 100 µl of TMB (tetramethyl-benzidine) reagent was dispensed into each well 
and gently mixed for 10 seconds and incubated at on orbital micro-plate shaker 
in the dark for 20 minutes. 
11- The reaction was stopped by adding 100 µl of stop solution to each well. 
The optical density was read at 450 nm with a microtiter plate reader within 15 
minutes. 
3.6. Statistical analysis: 
The mean and standard deviation of H-FABP and Mb were computed. The non-
parametric of Mann-Whitney U test for dependent variables was performed with 
SPSS version 17.0 to test for significant differences between the values of H-
FABP and Mb or the ratio of these markers, immediately before and 1 hour after 
running on treadmill in both steps of current study. P<0.05 (*) was considered to 
indicate statistical significance. 
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4. Results 
 
 
 
4.1. Characteristic issues of muscle injury markers: 
As mentioned above, in the current study, firstly we reviewed some of muscle 
injury markers, as were explained in section 2. Their characteristic issues have 
been summarized below: 
4.1.1. CK: 
o High CK activity is detectable in muscle, heart and brain. 
o CK activity is also detectable in serum. 
o CK-MM is the main isoenzyme in muscle.  
o CK is the most common serum marker for skeletal muscle injury, but CK is 
not an ideal marker for several reasons: 
o Lack of tissue specificity 
o Inability to reveal damage to specific skeletal fiber types 
o In low concentration of gluthatione, CK has low value. 
4.1.2. Mb: 
o Mb is a small monomeric, respiratory hem protein. 
o Aerobic slow-twitch type 1 (and 2a) fibers are the primary source of plasma 
Mb. 
o It has been suggested that Mb is an excellent marker of acute muscle 
damage or increased muscle membrane permeability.  
o Mb is a sensitive but non-specific marker of AMI. 
o Mb can modulate the angiogenic response to ischemia. 
4.1.3. Fast myosin:  
o Myosin is the major structural protein in muscle. 
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o Myosin is more sensitive and more stable marker than CK and Mb in blood. 
o Fast myosin is a totally specific marker for skeletal muscle. 
o MHC shows a delayed increase after exercise-induced muscle injury. It is 
therefore not suitable for early diagnosis. 
4.1.4. α-actin: 
o Actin is a globular protein found in eukaryotic cells. 
o α-actins are found in muscle tissues. 
o α-actins are a major constituent of the contractile apparatus. 
o α-actin is abundant in the cell. 
o α-actin is a new and reliable marker of skeletal muscle damage. 
o Discrimination between skeletal and cardiac muscle damage can be done 
by the combined use of α-actin and TnI. 
4.1.5. sTnI: 
o TnI is the inhibitory subunit of troponin. 
o TnI is only expressed in striated muscle fibers. 
o ssTnI is produced in slow-twitch (ST) fibers. 
o fsTnI is produced in fast-twitch (FT) fibers. 
o Activity-induced injury preferentially injured FT fibers. 
o The release or clearance of sTnI can be affected by some conditions such 
as renal failure, compartment syndrome, and cardiac abnormalities. 
4.1.6. H-FABP: 
o FABP can reversibly and non-covalently bind fatty acids and transport 
 them from the cell membrane to mitochondria. 
o FABP is one of the novel and promising plasma markers for detection of 
tissue injury. 
o Among the members of the FABP family, H-FABP is most widely distributed 
within the organism. 
o H-FABP is abundantly expressed in cardiomyocytes, but to a lesser extent 
in skeletal muscles and other tissues with an active fatty acid metabolism. 
o H-FABP appears to be a valid serum biomarker for the early diagnosis of: 
AMI, stroke, and acute muscle damage. 
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4.1.7. Mb/H-FABP ratio: 
o Discrimination between myocardial and skeletal muscle injury. 
o The Mb to H-FABP ratio seems to be useful to identify the type of muscle 
injured. 
4.2. The results of practical part of project: 
Our study in practical part comprised 5 well trained athletes who performed all 
steps of test, completely.  Firstly, they run on a treadmill with increased velocity at 
regular intervals (the velocity was increased 0.4 m/s every 5 minutes). The heart 
rate was controlled regularity and blood samples were taken in small amounts 
from the ear of participants at each increment to determine the lactate 
concentration with an automatic analyser. We determined their AT via graded 
running on a treadmill in this step.  
 
Table 3: Heart rate and blood lactate concentration of participants on graded 
running for determining of AT 
Velocity 
(m/s) 
Time 
(min) 
Heart rate (bpm) Lactate concentration (mg/dl) 
S-1 S-2 S-3 S-4 S-5 S-1 S-2 S-3 S-4 S-5 
1.6 5 100 102 113 102 98 0.92 0.91 1.16 0.95 0.84 
2.0 5 104 129 127 110 127 0.74 1.69 1.33 1.12 0.95 
2.4 5 121 132 130 122 139 0.88 2.16 1.33 1.25 1.35 
2.8 5 132 150 146 129 151 1.28 2.84 2.35 1.55 2.21 
3.2 5 147 165 163 145 161 2.36 4.62 4.32 2.33 3.72 
3.6 5 162 172 174 165 175 3.92 6.05 5.98 3.89 6.30 
4.0 5 170 --- --- 172 --- 5.27 --- --- 5.45 --- 
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Table 4: The AT values (m/s) of participants determined via graded running on a 
treadmill 
Subject S-1 S-2 S-3 S-4 S-5 
AT value 3.6 3.05 3.10 3.6 3.25 
 
At the next steps prolonged constant-load exercise bouts were done by all 
participants. 
The first and second constant-load exercise bouts consist of 30 minutes of running 
on treadmill at a velocity of 70% of AT and an elevation of 1% [LH: 70%AT, +1%] 
and 90% of AT and an 10% declination [HD: 90%AT, -10%], respectively.  
 
Table 5: The velocity and duration of running of participants at the first and 
second bout of   constant-load exercises 
Step,  
Velocity &  
Duration 
Subject 
Low Intensity High Intensity 
Velocity 
(m/s) 
Duration 
(min) 
Velocity 
(m/s) 
Duration 
(min) 
S-1 2.50 30 3.24 30 
S-2 2.14 30 2.75 30 
S-3 2.17 30 2.79 30 
S-4 2.50 30 3.24 30 
S-5 2.28 30 2.95 30 
 
Capillary blood sampling was done immediately before the start of the test at each 
bout of constant-load exercises and again one hour after the test. The serum were 
obtained and frozen until assayed. The serum count of H-FABP and Mb were 
measured by quantitative tests based on the principle of a solid phase enzyme-
linked immunosorbent assay (ELISA). Tables 6 and 7 showed the serum count of 
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those two above mentioned markers in low and high intensity exercises, 
respectively. Also the ratios of Mb over H-FABP have been showed in Table 8.  
 
Table 6: The serum concentrations (ng/ml) of Mb and H-FABP in participants at 
the first step of test [LH: 70%AT, +1%] 
Sampling’s time  
& Marker  
Subject 
Before the running After running 
Mb H-FABP Mb H-FABP 
S-1 28.02 6.25 39.26 5.87 
S-2 33.18 7.74 49.28 7.91 
S-3 25.00 6.25 31.02 9.63 
S-4 32.13 5.93 39.63 6.78 
S-5 87.33 10.70 47.54 12.25 
 
Table 7: The serum concentrations (ng/ml) of Mb and H-FABP in participants at 
the second step of test [HD: 90%AT, -10%] 
 
Sampling’s time  
& Marker  
Subject 
Before the running After running 
Mb H-FABP Mb H-FABP 
S-1 28.52 6.03 162.68 14.50 
S-2 59.62 12.32 83.96 16.56 
S-3 31.36 4.85 134.79 10.34 
S-4 26.39 7.36 30.87 8.54 
S-5 32.93 9.33 56.68 10.83 
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Table 8: The ratio of serum mean values of Mb over H-FABP in participants at 
both steps [LH: 70%AT, +1%; HD: 90%AT, -10%] 
 
Intensity of exercise 
& Time of S* 
Subject 
LH: 70%AT, +1% HD: 90%AT, -10% 
Before 
the 
running 
After running 
Before the 
running 
After running 
S-1 4.49 6.69 4.73 11.21 
S-2 4.29 6.23 4.84 5.07 
S-3 4.00 3.22 6.46 13.07 
S-4 5.41 5.84 3.58 3.61 
S-5 8.16 3.88 3.53 5.23 
*Sampling 
 
 
The serum mean values and the ratio of those two above mentioned markers have 
been indicated in Table 9 and Table 10, respectively.  
In the present study we found no significant increase in serum count of either Mb 
or H-FABP in participants at the low intensity/ horizontal running of test. At the 
high intensity/ downhill running of test, we observed significant differences 
between the serum count of Mb and also H-FABP, pre and post running, in 
participants (p<0.05) (Figure 9). 
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Table 9: The serum mean values of Mb and H-FABP in participants 
Concentrations and time 
of sampling 
Marker - % AT 
Mean ± SD (ng/ml) 
Before running 1 h after running 
Mb 
[LH: 70% AT, +1%] 
41.13 ± 26.03 41.34 ± 7.33 
Mb 
[HD: 90%AT, -10%] 
35.76 ± 13.57 93.79 ± 54.45 (*) 
H-FABP 
[LH: 70% AT, +1%] 
7.37 ± 1.99 8.48 ± 2.52 
H-FABP 
[HD: 90%AT, -10%] 
7.98 ± 2.94 12.16 ± 3.28 (*) 
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H‐FABP
0
20
40
60
80
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Figure 9: Comparison of serum mean values (ng/ml) of Mb and H-FABP in 
participants at the second step of test [HD: 90%AT, -10%] 
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There was also a significant difference between the ratio of serum count of Mb 
over H-FABP in participants at this step (p<0.05) (Figure 10).  
 
Table 10: The ratio of serum mean values of Mb over H-FABP in participants 
Values at the  
relevant time  
Ratio - % AT 
Ratio ± SD 
Before running 1 h after running 
Mb/H-FABP 
[LH: 70% AT, +1%] 
5.27 ± 1.69 5.17 ± 1.53 
Mb/H-FABP 
[HD: 90%AT, -10%] 
4.35 ± 0.73 8.36 ± 3.95 (*) 
  
 
 
Figure 10: Comparison of the ratio of serum mean values of Mb over H-FABP in 
participants at the second step of test [HD: 90%AT, -10%] 
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5. Discussion 
 
 
 
This thesis is divided into two main sections: theoretical part and practical part. 
5.1. Theoretical part 
In theoretical part some of muscle injury markers were reviewed and their 
characteristic issues summarized and advantages and disadvantages of those 
markers noted. In practical part of the current project, the effects of low and high 
intensity exercises on serum mean values of Mb and H-FABP were evaluated. 
On the basis of this premise, in section 1 these two later markers were more 
widely reviewed than the other markers and especially some immunological 
assays for determining of them such as ELISA were reviewed.   
A muscle has the capacity only to contract or not contract (relax). [4] When it 
contracts, the muscle always applies tension toward its middle. This may result in 
a concentric contraction, meaning the muscle shortens, or an eccentric 
contraction, meaning that while it applies tension the muscle gets longer because 
the resistance is greater than the tension. A muscle is said to contract isotonically 
(dynamically) when it either shortens or lengthens, and thus movement occurs, or 
isometrically (statically) when no movement occurs because the tension is not 
sufficient to overcome resistance against the muscle. Skeletal muscle is a 
remarkable tissue. Skeletal muscles are essential tissues that determine human 
performance. Without this important part of body, no one can dose any activity 
needed for daily life. Muscle injuries account for 30% of all sporting injuries. [109] 
Muscle injuries can be classified into those due to indirect trauma and those due to 
direct trauma. Indirect trauma injuries include delayed onset muscle soreness and 
muscle strain. Direct trauma injuries are subdivided into muscle contusion and 
muscle laceration. Muscle injuries may be assessed by several techniques. A 
musculoskeletal assessment requires a proper and thorough systematic 
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examination of the patient. A correct diagnosis depends on a knowledge of 
functional anatomy, an accurate patient history, diligent observation, and a 
thorough examination. The differential diagnosis process involves the use of 
clinical signs and symptoms, physical examination, a knowledge of pathology, and 
mechanisms of injury, provocative and palpation (motion) tests, and laboratory and 
diagnostic imaging techniques. It is only by a complete and systematic 
assessment that an accurate diagnosis can be made. [110]  
The diagnosis of muscle injuries can be done through several techniques:  
o Medical examination: Physical examination provides information about the 
injury and suggests appropriate further investigation. 
o Imaging techniques: For example magnetic resonance imaging (MRI) 
provides major insights into the pathogenesis of disorders affecting the 
musculoskeletal system. MRI supplements investigations for the differential 
diagnosis of neuromuscular diseases. [111] Ultrasonography and MRI are 
both useful imaging modalities in defining the location, extent and severity 
of muscle injury. [110]  
o Laboratory tests for blood analysis: These tests tell us about the severity or 
grade of lesion. [12, 112]  
Advances in biological markers (biomarkers) have facilitated the assessment of 
associations between environmental exposures and potential health effects by 
improving accuracy and precision of measures and helping to identify high-risk 
groups in exposed populations. [20]  
Obviously, the best treatment can be provided if the injury is diagnosed in its early 
stages. Early diagnosis of skeletal muscle injuries, one of the causes of athlete’s 
inaction, and acute myocardial infarction (AMI), one of the most important mortality 
factors, are based on the recognition of muscle injury markers.  
Muscle injury biochemical markers also play an important role in helping trainers 
make a good decision about the sportsmen and sportswomen.  
The release of muscle content proteins is occurred after muscle injury. The both 
lysosomal (cathepsin C, D) and non-lysosomal proteases increase the rates of 
protein degradation and amino acid oxidation that occur during exercise. Protease 
calpain may initiate the exercise-induced changes in myofibrillar turnover and 
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organelle disassembly. In vitro, calpain cleaves a variety of substrates: receptor 
proteins, soluble and membrane associated enzymes, cytoskeletal proteins and 
myofibrillar proteins. Basically, the time and amount of extracellular release and 
clearance from plasma of biochemical markers of muscle damage depend on the 
biochemical characteristics of the molecule, the level of training, the type, intensity 
and duration of exercise, as well as on the period of recovery after training. [113] 
CK and Mb are routinely used to assess the injury in laboratory tests. Although 
some other markers such as fast myosin, sTnI, α-actin and H-FABP are also 
sometimes used in laboratory tests, their use in early assessment of muscle 
injuries is a challenge. In the current study we firstly reviewed some of muscle 
injury markers and their characteristic issues were summarized and then in 
practical part of project the serum concentrations of Mb and H-FABP were 
evaluated in athletes after low and high intensity exercises.  
5.1.1. CK:  
CK enzyme activity is detectable in muscle, heart and brain and also in 
serum. CK-MM, CK-BB and the hybrid form of CK-MB are characteristic for 
muscle, brain and heart, respectively. Monitoring of CK and characterisation of its 
isoenzymes is widely used in the diagnosis of cardiomyopathies, 
encephalopathies, and muscle disease. [114] CK is released slowly from skeletal 
muscle after exercise. [34] In veterinary medicine, serum CK activity is mostly 
used to assess skeletal muscle damage. Elevation of CK after exercise is a well-
known phenomenon in healthy subjects, in humans as well as in animals. 
Eccentric activation of muscle has been widely implicated as the cause of large 
increases in plasma CK after exercise. [115] But CK is not an ideal marker for 
several reasons: 
o Lack of tissue specificity: CK-MM is present in high concentrations in 
both skeletal and cardiac muscle. [116]  
o Inability to reveal damage to specific skeletal fiber types. 
o CK has low value in low concentration of gluthatione. 
CK activity may also be affected by different variables such as oestradiol levels, 
daily training, sex or type of sports discipline. [43] It is notable that the resting CK 
levels are higher in elite and professional athletes, but the significant increases of 
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CK occurring after exercise are usually lower in trained subjects than in untrained 
subjects. [113] 
5.1.2. Mb:  
Mb is a ubiquitous heme protein with a molecular weight of 17.800 kilodaltons, 
constituting about 2% of the total muscle protein. [116, 117]   It has been 
suggested that Mb is an excellent marker of acute muscle damage or increased 
muscle membrane permeability. Though Mb has long been recognized as a 
cardiac marker, it has been limited in its use by poor specificity owing to its 
presence in skeletal muscle. A peak of Mb occurs shortly after damage and 
disappears rapidly. [39] However, Mb is also released in other disease states, 
including AMI, open heart surgery, muscular dystrophy, renal failure, shock and 
trauma. [118]   
5.1.3. Fast myosin:  
MHC is a structurally bound contractile protein of the thick filaments, and an 
increase in plasma MHC concentrations after exercise, therefore, indicates both 
membrane leakage and degradation of the contractile apparatus. [45] However, 
MHC shows a delayed increase after exercise-induced muscle injury. Therefore, 
MHC is not suitable for early diagnosis of muscle injuries.  
5.1.4. α-actin:  
α-actin is an abundant protein in the muscle, where it represents more than 20% of 
all cell proteins. [23] The presence of skeletal α-actin in blood stream may be a 
specific marker of skeletal muscle damage. Discrimination between skeletal and 
cardiac muscle damage can be done by the combined use of α-actin and TnI. 
5.1.5. sTnI:  
sTnI is a regulatory protein that is only expressed in striated muscle fibers. [119]  
A marked increase of sTnI in patients with myoskeletal injury, with greater 
responses occurring for the bone than for the soft-tissue injuries. Marked increase 
in sTnI can be detected within 2-6 hours from the onset of exercise-induced 
muscle injury. [45] In contrast to all other available markers, sTnI is a protein 
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unique to skeletal muscle. sTnI may be an early marker for skeletal muscle 
damage. The release or clearance of sTnI can be affected by some conditions 
such as renal failure, compartment syndrome, and cardiac abnormalities. 
5.1.6. H-FABP:  
The soluble cytoplasm of skeletal and cardiac muscles and also some other tissue 
cells contains low-molecular mass proteins able to bind long chain unesterified 
fatty acids, that are called FABP. [120] FABP comprises 15% to 30% of 
cytoplasmic proteins. [125] In nine different identified cytoplasmic FABP types, H-
FABP is most widely distributed within the organism.  H-FABP appears to be a 
valid serum biomarker for the early diagnosis of: AMI, stroke, and acute muscle 
damage. It is a more suitable marker than CK-MB or Mb for early assessment of 
post-operative myocardial infarction. [118] The concentration of FABP in the 
plasma of healthy people is relatively low (2-6 µg/l). [120]  
5.1.7. Mb/H-FABP ratio:  
Mb and H-FABP, both are present in the heart and skeletal muscle. However, 
concentration of Mb is approximately two-fold lower in cardiac than skeletal 
muscle (2.5 and 4.0 mg/g wet weight of tissue) but the concentration of H-FABP in 
the heart is several-fold higher than that in the skeletal muscles (0.5 vs. 0.05-0.2 
mg/g wet weight). [120, 121] In addition, the normal plasma concentration of H-
FABP (<5 µg/l) is 10-15-fold lower than that of Mb (20-80 µg/l). Both proteins are 
released into plasma after injury at about the same time and in a ratio similar to 
the concentration of the proteins in the tissue of origin, therefore the measurement 
of the Mb/H-FABP ratio could be useful for discriminating between cardiac and 
skeletal muscle damage. However, the use of this ratio should not be a rigid 
criterion. 
5.2. Comparison between above mentioned markers: 
It is much interesting to make a diagram to compare the time course elevation of 
those above mentioned markers. To my knowledge there is no complete time 
course elevation relevant data for all those markers. Some accessible data will be 
shown below. 
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Sorichter and colleagues [45] compared the median peaks of CK, Mb, MHC and 
sTnI after downhill and level running to evaluate the muscle injury (Table 11). 
 
Table 11: Comparison of peak values of muscle injury markers 
Time course value 
Marker 
Time to peak Value 
Downhill 
running 
Level 
running 
CK (activity) [U/l] 24 h 309 178 
Mb [µg/l] 6 h 466 98 
MHC [µU/l] 48 h 1021 501 
sTnI [µg/l] 6 h 27.3 6.6 
 
 
 
Eston, et al. [115] noted that the elevation of CK is started after 2 days of injury 
and its peak value, 1500-11000 U/l, reached after 4-5 days. Lippi and colleagues 
[113] observed that the peak value of Mb is reached after 3 hours and returned to 
normal range in 24 hours. Kirwan and colleagues [122] compared CK activity and 
Mb concentration after two unilateral isometric knee extension exercises. They 
observed different values for CK and Mb after 6 hours of those two above 
mentioned exercises. Martinez-Amat, et al. [23] compared the activity of CK and 
concentrations of Mb, cTnI and α-actin between muscle damage and control 
groups (Table 12). 
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Table 12: Comparison of muscle injury markers in muscle injury group and 
controls 
 
Group 
Marker 
Muscle damage group Control group 
CK (IU/l) 
2041.9 ± 2194.5 
Range: 517 – 8943 
105.5 ± 103.9 
Range: 15 - 545 
Mb (ng/ml) 
891.815 ± 887.449 
Range: 3.633 – 58.6 
28.8697 ± 24 
Range: 79.8 – 5.7 
cTnI (ng/ml) 
0.035 ± 0.031 
Range: 0.001 – 0.160 
0.0213 ± 0.0199 
Range: 0.001 – 0.085 
α-actin (ng/ml) 
1968.51 ± 515.25 
Range: 854 – 2.594 
600.90 ± 532.97 
Range: 0.00 – 1.359 
 
 
Of course, Sorichter, et al. [64] evaluated muscle injury markers and showed their 
time course concentrations in a diagram. In their study peak FABP concentrations 
in individual subjects correlated with peak CK levels. Chu and colleagues [118] 
reported the time course elevation and peak of markers. As they reported the 
initial elevation for FABP, Mb, cTnI, CK-MB, occurred within 1.5-3, 1-3, 3-6 and 3-
8 hours, and also the time to peak of those markers were 6-8, 5-8, 14-18 and 9-24 
hours, respectively. Martinez-Amat, et al. [43] compared the muscle injury markers 
in sportspeople and non sportspeople (Table 13). 
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Table 13: Comparison of muscle injury markers between sportspeople and non 
sportspeople 
Group 
Marker 
Injured non- 
sportspeople 
Injured 
sportspeople 
Uninjured 
sportspeople 
Uninjured non- 
sportspeople 
Mb (ng/ml) 891.8±154.4 50.2±6.7 41.2±2.1 28.8±3.2 
CK (IU/l) 2041.9±382.01 138.3±12.6 240.8±17.8 105.5±18.08 
TnI (ng/ml) 0.035±0.005 0.016±0.001 0.017±0.001 0.021±0.003 
α-actin 
(µg/ml) 
37.4±1.3 10.4±1.8 3.9±0.7 0.2±0.03 
 
Onuoha, et al. [119] compared the markers in three groups (Table 14).  
 
Table 14: Comparison of three markers in three groups 
  Group 
Marker 
Bone injury group Soft-tissue injury 
group 
Controls 
sTnI (ng/ml) 16±2 10±2 2±0.9 
CK (IU/l) 318±248 135±94 87±30 
Mb (ng/l) 96±60 47±55 40±33 
 
 
 
As mentioned above, there is not complete time course relevant data about the 
muscle injury markers. In existing data, there is a lot of diversity, due to some 
matters such as the type of muscle injured, intensity of exercise or physical activity 
and duration of exercise. Nevertheless, a diagram will be drawn below, showing 
the possibility and accuracy of use of those markers in early diagnosis of muscle 
injuries. 
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Figure 11: Comparison of the time course elevation of muscle injury markers 
 
5.3. Practical part: 
In practical part of the current study we observed that the serum concentrations of 
Mb and H-FABP and also the ratio of Mb over H-FABP is significantly different in 
subjects pre and I hour post running at high intensity/downhill running on treadmill 
[HD: 90%AT, -10%]. (Table15)  
Table 15: Comparison of Mb and H-FABP after high intensity exercise in athletes 
                     Time 
Marker 
Pre running 1 h Post running 
Mb 35.76 ± 13.57 93.79 ± 54.45 
H-FABP 7.98 ± 2.94 12.16 ± 3.28 
Mb/H-FABP 4.35 ± 0.73 8.36 ± 3.95 
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In practical part of the current study, the effects of low and high intensity exercises 
on plasma mean values of Mb and H-FABP were investigated.  
The results of this part of the current study showed that the concentrations of both 
Mb and H-FABP increase on high intensity/ downhill running in serum of the 
subjects. All subjects were volunteer sports students and trainer who all passed 
the health examinations and considered well-trained athletes. Therefore, we 
assumed that the elevation of serum mean values of the two above mentioned 
markers arise from skeletal muscles.  
To our knowledge this is the first time that the effects of low and high intensity 
exercises on serum concentrations of Mb and H-FABP, and subsequently 
assessment of muscle injury, have been evaluated in well trained athletes. It is 
well documented that eccentric muscle contractions produce skeletal muscle 
damage. [123] Sorichter and colleagues [64] showed for the first time that plasma 
FABP increases after physical exercise in healthy subjects and its pattern of 
release into and clearance from the blood is similar to that of Mb. Malek and 
colleagues [66] observed the increasing of H-FABP concentration on exercise in 
healthy subjects. As they reported the subjects had the H-FABP serum mean 
value of less than 7 ng/ml pre running, almost as much as we observed in our 
subjects pre running at both steps of our test.  
 Lippi and colleagues [113] measured some markers in their subjects. The mean 
values of Mb in the above mentioned showed to be elevated after a 21-km half-
marathon (36 ± 3, 102 ± 13, 104 ± 14 ng/ml at pre, post and 3 h after running, 
respectively). It is almost as much as we measured in our subjects at the high 
intensity/ downhill running of test.  
There is substantial evidence that eccentric contractions cause more damage than 
other types of contraction. An eccentric activation is the controlled lengthening of 
the muscle under tension. During downhill running the role of eccentric work of the 
anti-gravity muscles including knee extensors, muscles of the anterior and 
posterior tibial compartments and hip extensors, is accentuated. [115]  
In the current study, as it was expected, after the high intensity/ downhill running 
on treadmill, the serum counts of evaluated markers were significantly higher than 
that before the running. The elevation of mean ratio of serum concentrations of Mb 
over H-FABP was in agreement with the results found by Sorichter and colleagues 
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[65]. However, the ratios calculated by them were higher than ours. This might be 
due to the fact that Sorichter excluded the samples in which both proteins (Mb and 
FABP) had not been increased to at least twice their baseline values when 
calculating the ratio as done by Nieuwenhoven. [56]  
Moreover, the participants in Sorichter’s study ran on a treadmill set at a 16% 
decline, thus likely producing more damage in muscles’ cells than in our subjects 
as they ran on a treadmill set at a 10% decline.  
A limitation of this study is the small size of subjects and therefore it seems that 
the findings in our current study should be confirmed on a larger group of voluntary 
subjects. In addition, we did not measure the serum value of any especial 
biochemical marker of heart muscle injury, such as cardiac troponin I (cTnI) to 
compare to the serum mean values of Mb and H-FABP.  
In conclusion it can be suggested that simultaneous measurement of Mb and H-
FABP and additionally express them as the ratio of Mb over H-FABP might give 
trainers the best information about the degree of damage of skeletal muscles in 
sportsmen or sportswomen. 
Evidently, further investigation is needed to determine the real early assessment 
marker of muscle injury. An ideal marker of skeletal muscle injury would have the 
following characteristics [116] - It would: 
o Be found in high concentration in skeletal muscle 
o Not be found in other tissues, even in trace amounts or under pathological 
conditions 
o Be released rapidly after skeletal muscle injury 
o Be released in direct proportion to the extent of muscle injury 
o Persist in plasma for several hours to provide a convenient diagnostic time 
window, but not so long that recurrent injury would not be identified 
o Have a high sensitivity and specificity. 
Although skeletal muscle injuries occurring in sports, exercises and physical 
activities restrict many of sport players and also other people who do sport 
recreationally to do their favourite sports and exercises, researchers have not 
concentrated on this field. Nieuwenhoven and colleagues [56] (1995)   concluded 
that both Mb and H-FABP show a similar pattern of release into and clearance 
from plasma. In another study [67] (1994) they observed that the ratio of Mb 
Discussion   
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values over H-FABP is significantly different in cardiac muscle (4.5) compared to   
of that in skeletal muscles (21-73). They also reported that the ratio of the serum 
concentrations of Mb over H-FABP after myocardial injury is significantly different 
from that found when skeletal muscles are most likely injured, as the plasma ratios 
reflects the ratio in which the proteins occur in the injured tissue. It seems that 
these markers may open a new window to evaluate the skeletal muscle injuries. 
Yuan, et al. [65] (2003) compared the serum concentrations of CK to FABP in a 
junior group of rowers and concluded that FABP measurement will be more 
important for monitoring acute muscle damage among elite athletes after a single 
training session. Malek and colleagues [66] (2005) investigated whether H-FABP 
plasma concentration increases in healthy subjects after exercise. To my 
knowledge assessment of muscle injury markers for early evaluating of skeletal 
muscle injuries is challenging. Further studies are needed to investigate the whole 
potential role of blood markers in assessment of skeletal muscle injuries. 
Obviously achievement of optical blood skeletal muscle injury marker based on 
future researches in this field parallel to biochemical and immunological methods 
studies. Future studies will be aimed to access a very early assessment skeletal 
muscle injury marker in a very small amount of blood.   
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6. Summary 
 
 
 
Muscle injuries are one of the most common traumas in sports and can be 
produced by intense or even moderate physical activity, especially eccentric 
exercise. It is important not to ignore even mild sport injuries, because this can 
exacerbate injuries and cause them to become far worse, much longer lasting and 
harder to treat. Common acute injuries to skeletal muscle can lead to significant 
pain and disability. Obviously pain and disability restrict the athletes to do their 
favourite sport and physical activities. Early affective diagnosis and treatment of 
these injuries is a challenge. The diagnosis of muscle injuries can be done through 
several techniques: medical examination, imaging techniques and laboratory tests 
for blood analysis. Obviously, the best treatment can be given if the injury is 
recognized in its early stages. The recognition of muscle injury markers is the most 
effective factor to achieve this goal.  
In current study we reviewed some muscle injury markers published in recent 
decades, firstly.  
Creatine kinase (CK) and myoglobin (Mb) are routinely used to evaluate the 
injuries in laboratory tests. High CK activity is detectable in muscle, heart and 
brain. CK-MM is the main isoenzyme in muscle.  
It has been suggested that myoglobin (Mb) is an excellent marker of acute muscle 
damage or increased muscle membrane permeability.  
Although fast myosin is a totally specific marker for skeletal muscle, it shows a 
delayed increase after exercise-induced muscle injury. It is therefore not suitable 
for early diagnosis of muscle injury.  
α-actin is a new and reliable marker of skeletal muscle damage. Discrimination 
between skeletal and cardiac muscle damage can be done by the combined use 
of α-actin and troponin I (TnI). 
Summary   
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Troponin I (TnI) is only expressed in striated muscle fibers. Slow and fast skeletal 
TnI (ssTnI and fsTnI) are produced in slow- and fast-twitch (ST and FT) fibers, 
respectively. 
Fatty acid-binding protein (FABP) is one of the novel and promising plasma 
markers for detection of tissue injury. Heart-type (H)-FABP appears to be a valid 
serum biomarker for the early diagnosis of: AMI, stroke, and acute muscle 
damage. 
The ratio of Mb over H-FABP is significantly different in cardiac muscle (4.5) 
compared to of that in skeletal muscles (21-73). It seems that the ratio of serum 
mean values of Mb over H-FABP is a good marker to evaluate the cardiac and 
skeletal muscle injuries. 
In practical part of the current study we evaluated the changes of serum mean 
values of Mb and H-FABP in a group of well trained athletes after low and high 
intensity exercises. The serum mean values of Mb and H-FABP and also the ratio 
of Mb over H-FABP were significantly increased after high intensity exercise in our 
subjects. It can be assumed that these two latter markers and expression of them 
as a ratio of Mb over H-FABP could give trainers a better diagnostic view of the 
players.  
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